PolymarketKullanılabilirliği kontrol etKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreVeri kalitesi uyarısıCanlı kotasyon yok
5 Eki 2026 22:11 UTC itibarıyla veriler · politika pm-quality-4
Güncel ima edilen olasılık
June 30, 83%
June 30, 83%Piyasa kalitesi
≤49 / 100
Düşük kalite24s Hacim
—
Likidite
₺384,9 B
Orta likiditeAlış / Satış
82.0% / 83.0%
Spread
1.0 pt
Dar spreadYorumlar
0
Piyasa verileri
5 dakika önce güncellendi
19 Ağu 26 18:47 UTC1 Tem 27 03:59 UTC
Trendler
İşlem platformu koşulları
Kaynak: Polymarket
Bu koşullar yalnızca bilgi amaçlıdır; CoinRithm deneme işlemlerinde kendi kurallarını uygular.
- Minimum emir (pay):
- 5
- Fiyat adımı:
- 1 yüzde puan
- İşlem ücreti:
- Evet
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiKurallar
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.